Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide

An analysis of the SWOG S1216 study supports that a deep prostate-specific antigen response at 3 or 7 mo after starting treatment for metastatic hormone-sensitive prostate cancer is prognostic for overall survival, regardless of front-line treatment received with androgen deprivation therapy.